Literature DB >> 24327568

A 4-MicroRNA signature can discriminate primary lymphomas from anaplastic carcinomas in thyroid cytology smears.

Ambrogio Fassina1, Rocco Cappellesso, Francesca Simonato, Maayan Siri, Laura Ventura, Francesca Tosato, Lill-Tove Busund, Maria Rosa Pelizzo, Matteo Fassan.   

Abstract

BACKGROUND: Anaplastic thyroid carcinoma (ATC) and primary thyroid lymphoma (PTL) are uncommon tumors of the thyroid gland with several overlapping clinical and pathologic features that may render their differentiation difficult in fine-needle aspiration (FNA) cytology. MicroRNA (miRNA) signatures have been recently reported as useful diagnostic tools applied to cytology specimens.
METHODS: Smears of 23 ATCs, 14 PTLs, and 20 non-neoplastic materials with multinodular goiter (MNG) were retrieved and classified based on their cytologic features and flow cytometric profiles. The ATC-related expression of hsa-miR-26a, hsa-miR-146b, hsa-miR-221, and hsa-miR-222 was quantified using quantitative reverse transcriptase-polymerase chain reaction analysis.
RESULTS: All miRNAs were remarkably up-regulated in ATC samples compared with PTL samples (P < .01). Moreover, expression levels of hsa-miR-146b, hsa-miR-221, and hsa-miR-222 were significantly higher in ATCs than in MNG samples (P < .01). Significant down-regulation of hsa-miR-26a was observed in PTLs compared with MNG samples, whereas hsa-miR-146b was overexpressed. Receiver operating characteristic analysis was used to determine the optimal cutoff for distinguishing ATC from PTL. The estimated receiver operating characteristic thresholds displayed a sensitivity level greater than 0.80 in achieving a diagnosis of PTL, allowing the correct identification of 13 of 14 PTL samples (93%).
CONCLUSIONS: Histotype-specific miRNA signatures can provide new insight into the molecular mechanisms of thyroid carcinogenesis. The tested 4-miRNA signature is a promising diagnostic tool for differentiating ATC from PTL and non-neoplastic MNG, even in the presence of scant material obtained from minimally invasive procedures.
© 2013 American Cancer Society.

Entities:  

Keywords:  fine-needle cytology; mantel zone lymphoma; microRNAs; primary thyroid lymphoma; thyroid cancer

Mesh:

Substances:

Year:  2013        PMID: 24327568     DOI: 10.1002/cncy.21383

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  10 in total

1.  Accurate likelihood inference for the volume under the ROC surface.

Authors:  Erlis Ruli; Laura Ventura
Journal:  Cancer Rep (Hoboken)       Date:  2019-12-10

2.  MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.

Authors:  Julia Ramírez-Moya; León Wert-Lamas; Pilar Santisteban
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

3.  p21 participates in the regulation of anaplastic thyroid cancer cell proliferation by miR-146b.

Authors:  Shiyang Wang; Yangjing Chen; Yanxia Bai
Journal:  Oncol Lett       Date:  2016-07-18       Impact factor: 2.967

4.  Effects of nutraceuticals on anaplastic thyroid cancer cells.

Authors:  Lorenzo Allegri; Francesca Rosignolo; Catia Mio; Sebastiano Filetti; Federica Baldan; Giuseppe Damante
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-02       Impact factor: 4.553

5.  Downregulation of microRNA‑33a promotes cyclin‑dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation.

Authors:  Yudong Wang; Xinliang Zhou; Baoen Shan; Jing Han; Feifei Wang; Xiaojie Fan; Yalei Lv; Liang Chang; Wei Liu
Journal:  Mol Med Rep       Date:  2015-09-07       Impact factor: 2.952

6.  Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis.

Authors:  Nurul-Syakima Ab Mutalib; Sri Noraima Othman; Azliana Mohamad Yusof; Shahrun Niza Abdullah Suhaimi; Rohaizak Muhammad; Rahman Jamal
Journal:  PeerJ       Date:  2016-06-15       Impact factor: 2.984

7.  Dissecting the biological relationship between TCGA miRNA and mRNA sequencing data using MMiRNA-Viewer.

Authors:  Yongsheng Bai; Lizhong Ding; Steve Baker; Jenny M Bai; Ethan Rath; Feng Jiang; Jianghong Wu; Hui Jiang; Gary Stuart
Journal:  BMC Bioinformatics       Date:  2016-10-06       Impact factor: 3.169

8.  Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears.

Authors:  Gila Lithwick-Yanai; Nir Dromi; Alexander Shtabsky; Sara Morgenstern; Yulia Strenov; Meora Feinmesser; Vladimir Kravtsov; Marino E Leon; Marián Hajdúch; Syed Z Ali; Christopher J VandenBussche; Xinmin Zhang; Leonor Leider-Trejo; Asia Zubkov; Sergey Vorobyov; Michal Kushnir; Yaron Goren; Sarit Tabak; Etti Kadosh; Hila Benjamin; Temima Schnitzer-Perlman; Hagai Marmor; Maria Motin; Danit Lebanony; Sharon Kredo-Russo; Heather Mitchell; Melissa Noller; Alexis Smith; Olivia Dattner; Karin Ashkenazi; Mats Sanden; Kenneth A Berlin; Dganit Bar; Eti Meiri
Journal:  J Clin Pathol       Date:  2016-10-26       Impact factor: 3.411

9.  miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4.

Authors:  Wei Ma; Xuzi Zhao; Leilei Liang; Guangzhi Wang; Yanyan Li; Xiaolong Miao; Yongfu Zhao
Journal:  Oncotarget       Date:  2017-04-25

10.  MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma.

Authors:  Lorenzo Nicolè; Rocco Cappellesso; Tiziana Sanavia; Vincenza Guzzardo; Ambrogio Fassina
Journal:  Oncotarget       Date:  2018-04-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.